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Abstract 
 
Aims: 
In rectal cancer, increasing the interval between the end of neoadjuvant chemoradiotherapy 
(CRT) and surgery could improve the pathological complete response (pCR) rates, allow full-
dose neoadjuvant chemotherapy, and select patients with a clinical complete response (cCR) 
for inclusion in a “watch & wait” program (W&W).  However, controversy arises from waiting 
more than 8 to 12 weeks after CRT, as it might increase fibrosis around the total mesorectal 
excision (TME) plane potentially leading to technical difficulties and higher surgical morbidity.  
This study evaluates the type of surgical approach and short term post-operative outcomes in 
patients with rectal cancer that were operated before and after 12 weeks post CRT. 
Methods: 
Patients from three centres (two in the UK, one in Portugal) who received rectal cancer surgery 
following neoadjuvant CRT between 2007 and 2016 were identified from prospectively 
maintained databases.  Preoperative CRT was given to patients with high risk for local 
recurrence (threatened CRM ≤2mm or T4 in staging MRI). The baseline characteristics and 
surgical outcomes of patients that were operated <12 weeks and ≥12 weeks after finishing 
CRT were analysed. 
Results: 
A total of 470 patients received rectal cancer surgery, of those 124 (26%) received 
neoadjuvant CRT.  Seventy-six patients (61%) were operated ≥12 weeks after end of 
neoadjuvant-CRT and 48 <12 weeks.  Patients in the ≥12 weeks cohort had a higher BMI (27 
vs 25, p=0.030) and lower lymph node yield (11 vs 14, p=0.001).  The remaining of the 
baseline characteristics were similar between the two groups (age, operating surgeon, gender, 
ASA grade, T stage, surgical approach, operation).  Operation time, blood loss, conversion 
rate, length of stay, 30-day readmission rate, 30-day reoperation rate, anastomotic leak rate, 
30-day mortality, CRM clearance, and ypT0 rates were similar between the two groups.  
Univariate and multivariate analysis showed that delaying surgery ≥12 weeks did not affect 
morbidity and mortality. 
Conclusion: 
In our cohort, there was no difference in short term surgical outcomes between patients 
operated before or after 12 weeks following CRT.  The type of surgical procedures and the 
proposed approach did not differ due to waiting after CRT.  Delaying surgery by ≥12 weeks is 
safe, feasible and does not result in higher surgical morbidity.  
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Introduction 
 
Neoadjuvant chemoradiotherapy (CRT) in rectal cancer can result in significant tumour 
regression and it has been advocated that it reduces the risk of local recurrence [1 - 4] , even 
after correctly performed total mesorectal excision (TME) as described by RJ Heald in 1982 
[5].  This has resulted in the widespread use of CRT for rectal cancer and whereas some units 
apply it more sparingly for cancers that threaten the mesorectal fascia (MRF) or invade 
adjacent structures [6], other units routinely use neoadjuvant CRT for all rectal cancers over 
cT2 or cN+ [7]. Increasing the interval between the end of neoadjuvant chemoradiotherapy 
(CRT) and surgery could improve the pathological complete response (pCR) rates, allow full-
dose neoadjuvant chemotherapy, and select patients with a clinical complete response (cCR) 
for inclusion in a “watch & wait” program (W&W) 
A significant proportion of patients receiving CRT will achieve pathological complete response 
(pCR), heralding an excellent prognosis due to low local and distant recurrence rates [8, 9] . 
Several studies have shown that the rate of patients achieving pCR could be improved by 
increasing the interval between end of CRT and surgery [10 - 13] and this was also 
demonstrated in a meta-analysis [14].  This rationale is based on the principle that while DNA 
damage occurs during irradiation, cellular lysis occurs within the next weeks [13, 15, 16].   
Identifying clinical complete responders (cCR) that would be suitable for a W&W strategy is 
also a matter of rising interest [17-19], adding to the rationale of waiting longer [20]. These 
cCR patients might benefit from non-operative management and intensive surveillance, 
avoiding permanent stomas, low anterior resection syndrome morbidity and adverse 
outcomes when quality of life issues are weighed [21].  
Finally, there is a growing body of evidence that some locally advanced rectal cancer (LARC) 
patients might benefit from full neoadjuvant chemotherapy. With this in mind, the canonical 6-
8 weeks waiting period after RT might not be enough to administer a full dose of induction or 
consolidation chemotherapy regimens [22 - 24].  
However, there is no consensus on the optimal timing to operate [25].  Surgeons have been 
historically reluctant to delay surgery beyond 8 weeks as it might increase fibrosis around the 
TME plane, arguing that it could potentially lead to intra-operative technical difficulties and 
higher surgical morbidity.   
While studies report that increasing the time interval to 8 weeks increased pCR rate without 
affecting patient morbidity [11, 26, 27], the GRECCAR-6 trial [28] showed that waiting until 11 
weeks after CRT did not increase pCR after surgical resection and was associated with higher 
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morbidity and worse specimen quality. Nevertheless, a recent population based study did not 
confirm the French observations [29].   
The aim of this study was to compare short-term outcomes of rectal cancer surgery after an 
interval of less than 12 weeks after neoadjuvant CRT versus a longer interval. 
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Methods: 
 
Consecutive patients from three centres (two in the UK, one in Portugal) who underwent 
elective cancer resection surgery following neoadjuvant CRT between 2007 and 2016 were 
identified from prospectively maintained databases.  Rectal cancer was defined as cancer 
present within 15 cm from the anal verge and confirmed in staging MRI. 
Data collection began when the surgeons participating in this study started working in their 
respective units.  This was from 2007 and 2012 for the UK centres and 2013 for the 
Portuguese centre.  Informed consent was obtained from all patients. 
Peri-operative care 
Formal oncological and physical assessment was taken by all patients prior to surgery.  Pre-
operative staging was performed by colonoscopy or CT colonography, computed tomography 
(CT) of the chest, abdomen, pelvis and magnetic resonance imaging (MRI) of the pelvis.  
All patient findings were discussed in the multidisciplinary team meeting before treatment 
commencement. Preoperative CRT was given to patients with high risk for local recurrence 
(threatened CRM ≤2mm or T4 in staging MRI). 
Patients included in the study had surgery performed by three colorectal surgeons (AP is a 
UK Lapco™ trainer & robotic proctor, having taught TQ and NF): one surgeon in each centre 
in the UK and one surgeon in Portugal. Surgery was open, laparoscopic, or robotic. Applied 
surgical modality was based on surgeon discretion. Minimally invasive TME was performed in 
a standardized fashion as described previously  [30, 31] . After pre-operative irradiation, all 
rectal resections with an anastomosis performed below the peritoneal reflection had a diverging 
ileostomy (or transverse colostomy) fashioned. 
Post-operative care was standardised, with patients entering a routine enhanced recovery 
programme based on the one described by Kehlet and Wilmore [32].  Patients were 
discharged home per set criteria for discharge.  
 
Outcome assessment 
The baseline characteristics and surgical outcomes of patients that were operated <12 weeks 
and ≥12 weeks after finishing CRT were analysed.  Data was collected prospectively.  
Baseline characteristics analysed were sex, age, BMI, ASA grade, operating centre and T 
stage.  Peri-operative data collected included operative time, estimated blood loss, surgical 
approach (open vs laparoscopic vs robotic), operation performed and conversion to open for 
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laparoscopic and robotic procedures (defined as any incision needed to either mobilise the 
colon or rectum or ligate the vessels). Post-operative clinical and pathological data examined 
included length of stay, 30-day readmission, 30-day reoperation, 30-day mortality, 
anastomotic leak, lymph node yield, ypT0 rate and circumferential resection margin (CRM) 
clearance.  
Patient selection 
No specific pre-CRT selection criteria were used to decide whether patients were operated 
<12 or ≥12 weeks after finishing CRT. Decision on time to operate following CRT completion 
was based on a shared-decision making process, including patient’s preferences and 
multidisciplinary team decision. One centre had an ongoing program of deferral of surgery and 
offered patients to enter a “watch and wait” approach in case of a cCR. 
 The 12 week cut-off point for group analysis was decided upon lack of surgical and short-
term outcomes data beyond this point, in published trials [11, 26-28]. Additionally, when 
considering a “Watch and Wait” surveillance program, the final decision of proposing this non-
operative management usually is taken at restaging around 12 weeks. 
Statistical analysis 
IBM SPSS version 22 (SPSS Inc., Chicago, IL, USA) and Microsoft Excel 2010™ were used 
for the statistical analysis.  Non-parametric data was expressed as median with interquartile 
range.  Baseline demographic and clinical characteristics were compared using χ2 test or 
Fishers exact test for categorical variables and Mann-Whitney U test for continuous variables.  
P values of <0.05 were considered statistically significant.  Univariate binary logistic regression 
analysis was performed to assess whether operative treatment delay (<12 or ≥12 weeks) 
affected morbidity and mortality, with morbidity and mortality defined as the presence of any 
of the following outcomes: 30-day reoperation, 30-day readmission, anastomotic leak and 30-
day mortality.  Following this, a multivariate model was applied were operative treatment delay 
was adjusted for all clinically relevant variables.  These included: operating centre, age, BMI, 
sex and ASA grade.  Age, BMI and ASA grade were included as continuous variables for the 
purpose of logistic regression analysis, with operating centre, (multinomial) and sex (binary) 
representing categorical variables.  The constant was included in the analysis model and analysis 
was performed on IBM SPSS version 22.  Data in logistic regression analysis are presented as odds 
ratio, 95% confidence interval and p value.  
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Results 
 
Four hundred and seventy patients underwent rectal resection surgery by the three surgeons included 
in this study in three participating units.  Neoadjuvant CRT was given to 124 (26%) of those patients, 
all of whom were included in the study.  Seventy-six patients (61%) were operated ≥12 weeks after 
end of CRT and 48 (39%) <12 weeks, as shown in the histogram - Figure 1. Median interval between 
CRT and surgery was 7 [6,11] weeks for the first group, and 15 [12,100] weeks for the latter.  
Baseline characteristics 
The baseline characteristics of the two groups are summarised in table 1.  With the exception of BMI, 
which was higher in the ≥12 weeks cohort (27 [IQR 24-29] vs 25 [IQR 22-28], p=0.030), the baseline 
characteristics of the two groups were broadly comparable. 
Peri-operative characteristics and outcomes 
The peri-operative characteristics of the two groups are summarised in table 2.  Operative time, 
estimated blood loss and conversion rate were not different.  The majority of the operations were 
performed laparoscopically in both groups and there were no differences between the two groups in 
terms of surgical approach and procedure. 
Post-operative clinical and pathological outcomes 
The post-operative characteristics of the two groups are summarised in table 3.  There were no 
differences in any of the post-operative clinical outcomes (length of stay, 30-day readmission rate, 30-
day reoperation rate, anastomotic leak rate, 30-day mortality rate) between the two cohorts.  In terms 
of pathological outcomes, CRM clearance and ypT0 rates were similar between the two groups but 
lymph node yield was less in the ≥12 weeks group (11 [IQR 8-15] vs 14 [IQR 12-19], p=0.001).  There 
was a total of five 30-day reoperations and two 30-day mortalities.  Reoperations included in the less 
than 12-week group a patient that received a laparotomy for fascial dehiscence and a patient that had 
a revision of a prolapsed stoma.  In the over 12 weeks group reoperations included a patient that had 
a laparoscopy for an abdominal abscess, a laparotomy for an anastomotic leak and a Hartman’s for an 
anastomotic leak.  Both 30-day mortalities were in the less than 12 weeks cohort and both were due 
to myocardial infractions.  
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Logistic regression analysis for morbidity and mortality 
Univariate logistic regression analysis showed that delaying surgery ≥12 weeks did 
not affect morbidity and mortality.  This was still the case in multivariate analysis 
when other clinically relevant factors were considered (operating centre, age, BMI, 
sex, ASA grade).  Findings are summarized in table 4.
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Discussion 
 
 Optimal timing to surgery following neoadjuvant CRT is controversial [25].  Although most 
studies seem to agree on an advantage on delaying surgery, the exact timing of the delay is up for 
debate [11, 13, 26].   
 Increasing the interval between the end of neoadjuvant chemoradiotherapy 
(CRT) and surgery could be an interesting approach to improve the pathological 
complete response (pCR) rates [33], allow a group of patients to benefit from full-
dose neoadjuvant chemotherapy [24, 34], and finally to select patients with a 
clinical complete response (cCR) for inclusion in a “watch & wait” program [20, 21]. 
Due to this shift of treatment paradigm in rectal cancer, surgery is sometimes being 
delayed longer and longer, as represented in Figure 1. This long tail in the histogram 
is due to the time inherently needed to take decisions in a “Watch & Wait” program: 
to operate a non-responder; or to operate a local “regrowth” after a clinical 
complete response.  
 In the present study we found no difference in the short term surgical 
outcomes, and morbidity and mortality, between patients operated before or after 
12 weeks following CRT. The finding of a slightly higher BMI at the time of surgery 
(27 vs 25) in the ≥12 weeks cohort could either be a chance finding, or could be 
related to patients having more time to recover and regain any weight loss after 
CRT.  
 Although the 3 surgeons performed a standardized TME, patients in the ≥12 
week group had a lower lymph node yield (14 vs 11, p=0.001).  Hypothetically this 
could  be the delayed effect of CRT, in which increasing interval has an incremental 
effect on inducing fibrosis in lymphatic structures.  However, this finding is not 
supported by any other studies [27, 28, 33].  
It is also worth mentioning that the anastomotic leak rate appears to be higher in 
the over 12 weeks cohort (0 vs 5.7%; p=0.547). Even though we recognize the chance 
of a type two error due to the limited sample size of the study, the p value indicates 
that there is an over 50% that this finding might be due to chance. 
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The GRECCAR-6 trial [28] is the only randomized trial, comparing a 7 vs 11 week interval after CRT in 
265 patients. The trial reports an increased postoperative morbidity for the longer interval (44.5% vs 
32%, p=0.04) and worse quality of mesorectal resection (complete mesorectum 78.7% vs 90%, 
p=0.016). Sphincter preservation, anastomotic leak and re-intervention rates were similar between 
the two groups.  The reported increased morbidity was primarily due to medical complications, such 
as urinary complications, and were mostly relatively minor (Dindo II), not requiring re-intervention or 
a longer length of stay. In our study, delaying ≥12 weeks did not affect morbidity and anastomotic leak 
rates, translating into a similar 30-day reoperation, length of hospital stay and 30-day readmission 
rate.   A possible explanation in this result discrepancy regarding morbidity might be that although in 
the GRECCAR-6 trial overall morbidity was higher in the 11-week group, this was primarily due to 
medical complications and specifically urinary complications, which did not affect re-intervention rate 
or length of stay.  In fact, looking at the Dindo classification, only Dindo II complications were higher 
in the 11-week group, with Dindo III, IV and V being higher in the 7-week group.  Considering that our 
dataset focuses on Dindo IIIb or above complications, or complications resulting in a readmission, this 
might justify the difference in terms of reported morbidity.  A 2016 meta-analysis of the available 
(non-randomized) series reported for the longer interval group no difference in R0 resection rate, DFS 
or surgical complications, and an increase in pCR. [14]  
Another study compared the short-term outcomes of an increasing number of extra cycles of 
chemotherapy (mFOLFOX6) after conventional neo-adjuvant CRT and before TME [33]. The study 
consisted of four groups, with the control group receiving surgery 6-8 weeks after CRT, and the three 
experimental groups having a median delay time of 11.1, 15.4 and 19.3 weeks after CRT respectively.  
The rate of pCR increased with a longer delay (18% vs 25% vs 30% vs 38%, p=0.0036), without affecting 
reported technical difficulty, blood loss, R0 rate, anastomotic leak rate and overall post-operative 
complication rate. Although the report describes an increased rate of pelvic fibrosis on a subjective 
fibrosis scale, this did not lead to an increased perceived difficulty as judged by the surgeons, and was 
not associated with postoperative complications.  
In the context of delaying surgery, it is worth mentioning the results of the Stockholm III trial [27], 
comparing the outcome of short course RT with immediate surgery, short course RT with delayed 
surgery, and traditional long course with delayed surgery. They reported a higher rate of general and 
surgical postoperative complications with the short course and immediate surgery as compared to the 
two other arms with delayed surgery. It should be noted however that the interval to surgery in this 
trial was only 4-8 weeks, much shorter than the intervals studied in the present report.  
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The last decade has witnessed a rising interest in organ preservation, either through a W&W policy 
for clinical complete responders after CRT [37], or through local excisions of the remaining scar [20]. 
Especially for the W&W policy a complete clinical response might not be evident at 6-8 weeks, as the 
bowel wall can still be in the healing phase. In very good responders the interval can be extended to 
8-12 weeks to improve the ability to diagnosis a clinical complete response [20]. Of the three centres 
in the present study one is actively offering the W&W approach to clinical complete responders and 
is recruiting patients for the International Watch & Wait Database (IWWD - www.iwwd.org). Some of 
the patients with good responses at 6-8 weeks will still have residual tumour at a second assessment 
and will require TME surgery after an interval of more than 12 weeks. One of the concerns of surgeons 
with this approach is that delayed TME surgery might become more difficult.  
The results of our study document that even when surgery is performed beyond the canonical 6-8 
weeks period, patients are not hindered by an increase in LOS, 30-day readmission, 30-day 
reoperation, or 30-day mortality. In terms of surrogate oncologic outcomes, we did not observe a 
difference in CRM clearance, despite a lower lymph node yield in the delayed surgery group. 
The limitations of the present study are related to the retrospective design and the possible selection 
bias in the short and long delay groups. Although retrospective, the data was collected from 
prospectively maintained databases, minimizing observation bias, and all consecutive patients were 
included to minimize selection bias. Furthermore, compared to GRECCAR-6 trial [28] a smaller number 
of patients were included in our study, increasing the risk of type 2 error in any of the outcomes.  
Another limitation is that we have not reported minor post-operative complications (Clavien-Dindo I-
II).  This is because on our data sets we only record complications that result in reoperation (Clavien-
Dindo grade IIIb or more) or complications resulting in a readmission.  As a result, minor complications 
(Clavien-Dindo grade I-II) or complications of resulting in reintervention (Clavien-Dindo grade IIIa) are 
not recorded unless leading to a readmission.  It is conceivable that the complications (Clavien-Dindo 
grade I-IIIa) would be reflected in a prolonged hospital stay or higher readmission rate, which was not 
the case in this study.  However, we do recognize that these complications may have significant 
consequences in the patient’s quality of life, without necessary leading to a higher length of stay or 
readmission rate. 
In summary, our study shows that delaying surgery after CRT by more than 12 weeks does not seem 
to compromise the short-term surgical outcome. In the context of organ preservation with a W&W 
policy it seems therefore logical to extend the observation interval to delay surgery to ≥12 weeks in 
patients with a good response to CRT. This allows a better assessment of the tumour biology and the 
healing of the bowel wall. More patients will become eligible for organ preservation and will retain a 
12 
better quality of life by avoiding major surgery.  Further research with larger sample sized studies are 
required to throw further light into whether delaying surgery after CRT affects the short-term surgical 
outcomes of rectal cancer patients.  Furthermore, it is important for future studies to investigate the 
functional outcomes of patients having delayed vs non-delayed surgery following CRT.  This is an area 
were there is very little evidence and could be an important deciding factor when consulting patients 
whether to delay or not delay their surgery. 
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Stengths: This study adds to the existing literature examining the safety of delaying surgery 
after CRT and is of special interest since it is a surgical cohort of patients operated according 
to a standardized TME technique that stretches the delay period to more than 12 weeks. 
Limitations: Our study is not a randomized controlled trial, adding potential bias to the 
selection of patients in the two groups. We were not able to collect the reason for delay in all 
patients.  
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